课题基金 / 基金详情

ACTG A5001 - LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) PROTOCOL

ACTG A5001 - LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) PROTOCOL
ACTG A5001 - 纵向连锁随机试验 (ALLRT) 方案
批准号:
7604369
负责人:
THOMAS A CAMPBELL
金额:
$21.38万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-07-01 至 2008-03-31

项目摘要

项目成果

THOMAS A CAMPBELL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The ALLRT protocol is a planned series of prospective meta-analyses and cross-protocol analyses of data to be collected from an established longitudinal and cross-sectional cohort of HIV-infected individuals who have been prospectively randomized into approved parent ACTG clinical trials, and who have agreed to be followed long-term for the purpose of evaluating clinical, virologic, immunologic, and pharmacologic outcomes associated with long-term treatment with potent antiretroviral therapies. All subjects initially entered into the ALLRT protocol will be participating concurrently in a parent ACTG study or have completed participation in a parent clinical trial within the previous 8 weeks. Subjects entered into the ALLRT protocol may have additional blood and data collected for clinical, virologic, immunologic, and pharmacologic evaluations. Long-term follow-up will continue within the context of parent ACTG protocols until those studies close or an endpoint is reached. For subjects entered into the ALLRT protocol who reach an endpoint on their parent protocol or their parent protocol participation otherwise ends, and for whom participation in an alternative ACTG randomized trial is not immediately available or feasible, long-term follow-up with clinical, virologic, immunologic, and pharmacologic monitoring will continue according to the schedule outlined in the ALLRT protocol. Subjects may subsequently enroll in additional randomized ACTG clinical trials over time and still maintain participation in the ALLRT protocol, with study visits timed to coincide as nearly as possible.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ACTG A5211-SAFETY AND EFFICACY OF SCH 417690 IN HIV-INF, TRTMNT-EXP SUBJCTS
  • 批准号:
    7719470
  • 项目类别:
  • 资助金额:
    $0.27万
  • 财政年份:
    2008
  • 负责人:
    THOMAS A CAMPBELL
  • 依托单位:
ACTG 362-METAB,CARDIOVAS&NEUROLCOMPLICA'S IN SUBJ'S W/PAST CD4 CELL
  • 批准号:
    7719416
  • 项目类别:
  • 资助金额:
    $0.44万
  • 财政年份:
    2008
  • 负责人:
    THOMAS A CAMPBELL
  • 依托单位:
ACTG A5095 -PROTEASE INHIBITOR-SPARING REGIMENS FOR THE INITIAL TREATMENT OF HIV
  • 批准号:
    7719426
  • 项目类别:
  • 资助金额:
    $0.07万
  • 财政年份:
    2008
  • 负责人:
    THOMAS A CAMPBELL
  • 依托单位:
EVALOF EFFICACY OF ONCE/DAY PROTEASE INHBTR& ONCE/DAY NONNUCLEOSIDE REVERSE
  • 批准号:
    7719467
  • 项目类别:
  • 资助金额:
    $1.93万
  • 财政年份:
    2008
  • 负责人:
    THOMAS A CAMPBELL
  • 依托单位:
海外基金